Cumberland Pharmaceuticals (CPIX) EBT (2010 - 2026)

Cumberland Pharmaceuticals (CPIX) has 17 years of EBT data on file, last reported at -$3.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBT fell 350.2% year-over-year to -$3.1 million; the trailing twelve-month figure through Mar 2026 stood at -$7.2 million (down 116.84% YoY), and the FY2025 full-year result was -$2.8 million, up 56.53% from the prior year.
• EBT eased to -$3.1 million in Q1 2026, from -$1.4 million in the prior quarter.
• In the past five years, EBT ranged from a high of $1.3 million in Q1 2025 to a low of -$6.3 million in Q4 2023.
• A 5-year average of -$1.4 million and a median of -$1.4 million in 2025 frame the typical range for EBT.
• Across the five-year window, EBT tumbled 1155.12% in 2024 and surged 166.31% in 2025, its largest moves.
• Tracing CPIX's EBT over 5 years: stood at -$2.4 million in 2022, then slumped by 160.29% to -$6.3 million in 2023, then jumped by 68.8% to -$2.0 million in 2024, then gained by 28.92% to -$1.4 million in 2025, then tumbled by 125.34% to -$3.1 million in 2026.
• Business Quant data shows CPIX's EBT at -$3.1 million in Q1 2026, -$1.4 million in Q4 2025, and -$1.9 million in Q3 2025.